Business
iRhythm Holdings Gains Wall Street Favor as Cardiac Monitoring Demand Surges
Morgan Stanley and Evercore ISI reaffirm bullish ratings on iRhythm, citing strong Q4 preliminary results and growth potential from its next-gen cardiac monitoring technology.